Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Emerging targets for COPD therapy.

Peter J Barnes1

  • 1National Heart and Lung Institute, Imperial College, London, UK. p.j.barnes@imperial.ac.uk

Current Drug Targets. Inflammation and Allergy
|February 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial dysfunction in lung ageing and disease.

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

COPD 2020: new directions needed.

American journal of physiology. Lung cellular and molecular physiology·2020
Same author

Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.

The Lancet. Respiratory medicine·2020
Same author

Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model.

Journal of immunology (Baltimore, Md. : 1950)·2020
Same author

Sex and gender: modifiers of health, disease, and medicine.

Lancet (London, England)·2020
Same author

Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach.

Journal of clinical medicine·2020
Same journal

Animal models of pulmonary emphysema.

Current drug targets. Inflammation and allergy·2007
Same journal

Epithelial mucus-hypersecretion and respiratory disease.

Current drug targets. Inflammation and allergy·2007
Same journal

Lung structural changes in chronic obstructive pulmonary diseases.

Current drug targets. Inflammation and allergy·2007
Same journal

Oxidants and COPD.

Current drug targets. Inflammation and allergy·2007
Same journal

Inflammatory mediators in chronic obstructive pulmonary disease.

Current drug targets. Inflammation and allergy·2007
Same journal

Inflammatory cells and chronic obstructive pulmonary disease.

Current drug targets. Inflammation and allergy·2007
See all related articles

New treatments for chronic obstructive pulmonary disease (COPD) are in development to reduce disease progression and suppress airway inflammation. These therapies target inflammatory cells, signaling pathways, and lung tissue damage.

Area of Science:

  • Pulmonary Medicine
  • Pharmacology
  • Inflammation Research

Background:

  • Current treatments for chronic obstructive pulmonary disease (COPD) do not halt disease progression or reduce inflammation in small airways and lung parenchyma.
  • Significant unmet needs exist for therapies that can modify the underlying pathology of COPD.

Purpose of the Study:

  • To review emerging therapeutic strategies for COPD targeting various pathological mechanisms.
  • To highlight novel drug candidates in clinical development for COPD management.

Main Methods:

  • Review of ongoing clinical trials and preclinical research for novel COPD treatments.
  • Categorization of therapies based on their molecular targets and mechanisms of action.
  • Discussion of challenges in drug delivery and biomarker development for COPD.

Related Experiment Videos

Main Results:

  • Multiple drug classes are in development, including anti-inflammatory agents (e.g., phosphodiesterase-4 inhibitors), cell signaling inhibitors (e.g., p38 MAPK, NF-κB inhibitors), and targeted therapies.
  • Specific approaches aim to reduce inflammatory cell influx, mucus overproduction, fibrosis, and lung destruction (emphysema).
  • Promising agents include antioxidants, nitric oxide synthase inhibitors, leukotriene antagonists, kinase inhibitors, and retinoids.

Conclusions:

  • Several novel therapeutic strategies targeting inflammation, cell signaling, fibrosis, and tissue destruction are in clinical development for COPD.
  • Effective drug delivery to the peripheral lung and the development of validated biomarkers are crucial for advancing new COPD therapies.
  • These emerging treatments offer potential to modify COPD progression and improve patient outcomes.